Physician profile
Kent A Kirk
NPI 1154340941
$3,644.35
in general payments reported to CMS, 2019-2025
26 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $33.27 · 2021: $415 · 2022: $492 · 2023: $645 · 2024: $1,505 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278 · Charitable Contribution: $1,133 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.94 |
| Charitable Contribution | $1,132.84 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microsurgical Technology, INC. | $1,132.84 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $491.03 | 2019-2023 | Tecnis Simplicity |
| Rxsight INC | $460.36 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Alcon Vision LLC | $415.04 | 2019-2024 | Rocklatan |
| Bausch & Lomb Americas INC. | $155.64 | 2022-2023 | Envista Mx60 Iol, Vyzulta |
| Novartis Pharmaceuticals Corporation | $131.97 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $101.07 | 2019-2023 | Flarex, Tobradex St |
| New World Medical,INC. | $82.37 | 2020-2024 | Kahook Dual Blade, Streamline, Clearpath |
| Thea Pharma INC. | $75.88 | 2022-2024 | Iyuzeh |
| Carl Zeiss Meditec, INC. | $58.44 | 2021 | |
| Horizon Therapeutics Plc | $57.20 | 2023 | Tepezza |
| Abbvie INC. | $56.79 | 2022-2025 | |
| Harrow Eye, LLC | $50.10 | 2024 | Vevye, Iheezo |
| Astellas Pharma US INC | $49.37 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $43.97 | 2025 | Xdemvy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumibird Medical INC. | $41.42 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.93 | 2019 | |
| Ocular Therapeutix, INC. | $34.13 | 2019-2024 | Dextenza |
| Beaver-Visitec International, INC. | $27.60 | 2025 | |
| Kala Pharmaceuticals, INC. | $23.92 | 2019 | |
| Glaukos Corporation | $23.19 | 2024 | Idose |
| Dompe US, INC. | $20.04 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $19.45 | 2025 | Quatera 700 |
| Oyster Point Pharma, INC. | $19.23 | 2023 | Tyrvaya |
| Allergan, INC. | $18.72 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.